about
The effect of angiotensin II receptor blockers on hyperuricemiaThe emerging role of biotechnological drugs in the treatment of goutHealthcare burden of depression in adults with arthritis.Treatment approaches and adherence to urate-lowering therapy for patients with gout.Any link of gout disease control among hypertensive patients and onset of end-stage renal disease? Results from a population-based studyHealth care utilization in patients with gout: a prospective multicenter cohort studyThe impact of gout on patient's lives: a study of African-American and Caucasian men and women with gout.Gout: a review of nonmodifiable and modifiable risk factors.A Systematic Review of the Economic and Humanistic Burden of Gout.Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis.Gout after living kidney donation: correlations with demographic traits and renal complicationsPharmacokinetics and Bioequivalence of Two Formulations of Febuxostat 40-Mg and 80-Mg Tablets: A Randomized, Open-Label, 4-Way Crossover Study in Healthy Chinese Male VolunteersPharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects"It's complicated" - talking about gout medicines in primary care consultations: a qualitative study.A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development PropertiesPhysical Function, Hyperuricemia, and Gout in Older Adults.Prophylaxis on gout flares after the initiation of urate-lowering therapy: a retrospective research.Validation of claims-based algorithms for gout flares.Comorbidity Burden in Trial-Aligned Patients with Established Gout in Germany, UK, US, and France: a Retrospective Analysis.A Point-of-Care Raman Spectroscopy-Based Device for the Diagnosis of Gout and Pseudogout: Comparison With the Clinical Standard Microscopy.Disease Control, Health Resource Use, Healthcare Costs, and Predictors in Gout Patients in the United States, the United Kingdom, Germany, and France: A Retrospective AnalysisA Randomized, Double-Blind, Active- and Placebo-Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout.Use of febuxostat in the management of gout in the United Kingdom.Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout.Discovery of a Flexible Triazolylbutanoic Acid as a Highly Potent Uric Acid Transporter 1 (URAT1) Inhibitor.Prevalence and associations of gout and hyperuricaemia: results from an Australian population-based study.Management of gout in the real world: current practice versus guideline recommendations.A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift.The 3-Year Incidence of Gout in Elderly Patients with CKD.Racial differences in health-related quality of life and functional ability in patients with gout.Cost Burden of Chronic Pain Patients in a Large Integrated Delivery System in the United States.Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomised controlled trail protocolEvaluation of healthcare costs and utilization for patients with gout: a population-based matched cohort study.Insights in Public Health: Hyperuricemia and Gout in Hawai'i.
P2860
Q26777082-BA727A89-BC49-4138-9917-B5D02F515001Q26825459-E802A3F7-FFCE-4845-AE97-A2E24F7CB151Q30238991-50675896-34D7-4466-952A-706AF309DCB4Q33597442-9C7EA5A4-9D2D-4FDD-B151-7BF309828CD7Q33655400-73B63FAF-6620-4C5E-966A-2E022F0B52BDQ33750100-DD800227-B765-4627-A03C-20EDE49778BEQ34502543-27B42BFD-BD8B-4785-B04E-8A4D52BBC176Q34609600-EA605289-62B1-427F-A950-ED250B56356AQ35629910-54C4BDCF-573B-44E8-8AE6-E79E755C5E9AQ35778899-334F145C-9BC3-4FEB-9A81-B6B6706FFE32Q35908386-9ADDEEFC-5649-41E8-896C-204D01FF95CAQ35956067-CC41E67E-8A51-4FCC-A464-075E3A186CA4Q36029222-DAB39273-EED1-4319-BAB9-F5D69933B3F0Q36108109-5DA7DF41-FE7F-4B51-B42F-9613CC32B298Q36230423-B741EE90-ACA5-4AF1-A1D8-3257E4A2BE32Q36421974-31360EE1-0A8F-49C3-99FF-E185777FADE5Q36493145-37F9C1BB-0115-45DC-859A-B9825FF80739Q37059151-01E3B216-E56E-412C-8DA4-E8304E751AF0Q37080656-AD277491-9B65-4310-9F6A-C71F446CB442Q37192640-4021D118-D6AE-4DE4-B226-8834AC4035DBQ37208467-FA00B74E-4426-4F53-A913-407831BFBF76Q37456247-2085D928-FB0D-4703-A3DB-FEF5CA3925D8Q37649899-35013700-7C87-4A37-9AEB-9C2B01DDCCECQ38365938-BBD0A1AE-1CCE-4B02-AE3A-B19BF254F128Q38730721-B90FAD42-031A-4638-BFE6-420F5FA2657BQ40109948-F3B6DC50-8315-40E8-A7FF-9392B836D892Q40291328-817D19C7-268D-43E6-A043-84C6F51E413EQ40311349-79D9F59E-6A37-40DC-A8C8-E4DB70FFF3C6Q40353089-A974891B-D267-41FD-894F-B0F41211B5C9Q40405506-B6A4548F-390E-47C5-801E-8A1EA38BD891Q40459480-743AA83A-8482-4569-AF19-0D436D27B021Q42650070-7C5205E5-0D18-4712-8503-55080A1E8AE8Q47780242-D1FA8587-F5DB-4897-BE22-5A21990FFC86Q55394775-4D081BCA-D10D-44F2-B81F-07991C86383A
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A revised estimate of the burden of illness of gout.
@en
A revised estimate of the burden of illness of gout.
@nl
type
label
A revised estimate of the burden of illness of gout.
@en
A revised estimate of the burden of illness of gout.
@nl
prefLabel
A revised estimate of the burden of illness of gout.
@en
A revised estimate of the burden of illness of gout.
@nl
P2093
P2860
P1476
A revised estimate of the burden of illness of gout.
@en
P2093
Albert Wertheimer
Michael A Becker
Robert Morlock
P2860
P356
10.1016/J.CURTHERES.2013.04.003
P577
2013-12-01T00:00:00Z